163 related articles for article (PubMed ID: 38552059)
21. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
Watson TR; Gao X; Reynolds KL; Kong CY
JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
[TBL] [Abstract][Full Text] [Related]
22. Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial.
Rini BI; Atkins MB; Plimack ER; Soulières D; McDermott RS; Bedke J; Tartas S; Alekseev B; Melichar B; Shparyk Y; Kondoh C; Langiewicz P; Wood LA; Hammers H; Silber CG; Haber B; Jensen E; Chen M; Powles T
Eur Urol Oncol; 2022 Apr; 5(2):225-234. PubMed ID: 34244116
[TBL] [Abstract][Full Text] [Related]
23. Real world treatment sequences and outcomes for metastatic renal cell carcinoma.
Lai GS; Li JR; Wang SS; Chen CS; Yang CK; Lin CY; Hung SC; Chiu KY; Yang SF
PLoS One; 2023; 18(11):e0294039. PubMed ID: 37992086
[TBL] [Abstract][Full Text] [Related]
24. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Rini BI; Plimack ER; Stus V; Gafanov R; Hawkins R; Nosov D; Pouliot F; Alekseev B; Soulières D; Melichar B; Vynnychenko I; Kryzhanivska A; Bondarenko I; Azevedo SJ; Borchiellini D; Szczylik C; Markus M; McDermott RS; Bedke J; Tartas S; Chang YH; Tamada S; Shou Q; Perini RF; Chen M; Atkins MB; Powles T;
N Engl J Med; 2019 Mar; 380(12):1116-1127. PubMed ID: 30779529
[TBL] [Abstract][Full Text] [Related]
25. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
[TBL] [Abstract][Full Text] [Related]
26. Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial.
Atkins MB; Plimack ER; Puzanov I; Fishman MN; McDermott DF; Cho DC; Vaishampayan U; George S; Tarazi JC; Duggan W; Perini R; Thakur M; Fernandez KC; Choueiri TK
Eur J Cancer; 2021 Mar; 145():1-10. PubMed ID: 33412465
[TBL] [Abstract][Full Text] [Related]
27. A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma.
Chan A; Dang C; Wisniewski J; Weng X; Hynson E; Zhong L; Wilson L
Am J Clin Oncol; 2022 Feb; 45(2):66-73. PubMed ID: 34991104
[TBL] [Abstract][Full Text] [Related]
28. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL
J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003
[TBL] [Abstract][Full Text] [Related]
29. Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population.
Fujiwara R; Yuasa T; Kobayashi K; Yoshida T; Kageyama S
Expert Rev Anticancer Ther; 2023 May; 23(5):461-469. PubMed ID: 37038721
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of Axitinib Therapy After Nivolumab for Patients With Metastatic Renal Cell Cancer.
Yasuoka S; Yuasa T; Fujiwara R; Komai Y; Numao N; Yamamoto S; Kondo Y; Yonese J
Anticancer Res; 2020 Nov; 40(11):6493-6497. PubMed ID: 33109588
[TBL] [Abstract][Full Text] [Related]
31. Cost Effectiveness of Treatment Sequences in Advanced Renal Cell Carcinoma.
Mason NT; Joshi VB; Adashek JJ; Kim Y; Shah SS; Schneider AM; Chadha J; Jim HSL; Byrne MM; Gilbert SM; Manley BJ; Spiess PE; Chahoud J
Eur Urol Oncol; 2023 Jun; 6(3):331-338. PubMed ID: 36797084
[TBL] [Abstract][Full Text] [Related]
32. Takotsubo syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab plus axitinib.
Airò G; Maffezzoli M; Lazzarin A; Bianconcini M; Greco A; Buti S; Leonetti A
Immunotherapy; 2022 Nov; 14(16):1297-1305. PubMed ID: 36408614
[TBL] [Abstract][Full Text] [Related]
33. Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysis.
Wang J; Li X; Wu X; Wang Z; Zhang C; Cao G; Zhang X; Peng F; Yan T
EBioMedicine; 2019 Sep; 47():78-88. PubMed ID: 31439476
[TBL] [Abstract][Full Text] [Related]
34. First-line therapy for elderly patients with advanced renal cell carcinoma in the immuno-oncology era: a network meta-analysis.
Fujiwara Y; Miyashita H; Liaw BC
Cancer Immunol Immunother; 2023 Jun; 72(6):1355-1364. PubMed ID: 36495342
[TBL] [Abstract][Full Text] [Related]
35. Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events.
Grünwald V; Voss MH; Rini BI; Powles T; Albiges L; Giles RH; Jonasch E
Br J Cancer; 2020 Sep; 123(6):898-904. PubMed ID: 32587360
[TBL] [Abstract][Full Text] [Related]
36. An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma.
Rosellini M; Tassinari E; Marchetti A; Tateo V; Nuvola G; Rizzo A; Massari F; Mollica V
Expert Opin Drug Saf; 2023 Apr; 22(4):279-291. PubMed ID: 37055875
[TBL] [Abstract][Full Text] [Related]
37. Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study.
Tamada S; Kondoh C; Matsubara N; Mizuno R; Kimura G; Anai S; Tomita Y; Oyama M; Masumori N; Kojima T; Matsumoto H; Chen M; Li M; Matsuda K; Tanaka Y; Rini BI; Uemura H
Int J Clin Oncol; 2022 Jan; 27(1):154-164. PubMed ID: 34800178
[TBL] [Abstract][Full Text] [Related]
38. Symptomatic methemoglobinemia in a patient with metastatic clear cell renal cell carcinoma treated with pembrolizumab and axitinib combination therapy: a case report.
Olsen TA; Martini DJ; Evans ST; Goldman JM; Bilen MA
J Med Case Rep; 2021 Feb; 15(1):72. PubMed ID: 33602288
[TBL] [Abstract][Full Text] [Related]
39. Recent pharmacological approaches for the treatment of renal cell carcinoma.
Alimohammadi A; Fajkovic H; Remzi M; Shariat S; Schmidinger M
Expert Rev Clin Pharmacol; 2022 Feb; 15(2):187-195. PubMed ID: 35285369
[TBL] [Abstract][Full Text] [Related]
40. Hypopituitarism induced by pembrolizumab plus axitinib in the treatment of metastatic renal cell carcinoma: A case report.
Hanawa K; Sawada N; Aikawa J; Otake Y; Kasai Y; Mochizuki K; Shimura H; Mochizuki T; Kira S; Mitsui T
Oncol Lett; 2024 Feb; 27(2):66. PubMed ID: 38192652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]